

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/524963	Applicant: Tonge et al
371 Filing Date: 02-18-2005	Attorney Docket No.: 100815-1P US
Examiner: Royds, Leslie A	Group Art Unit : 1614
Customer No.: 44992	Confirmation No.: 3567
Title: N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3-sulphonamide as an anticancer agent	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants refer to the Information Disclosure Statement Form PTO-1449 (copy enclosed) filed with the 371 Application Papers for this application on 18th February 2005. Copies of the references listed on the 1449 were not supplied at that time because Applicants believed the USPTO would receive them from WIPO. All the references listed were cited on the International Search Report.

Applicants recently received the Notice of Acceptance for this application and note that there was no indication that the USPTO had received these references from WIPO. Applicants therefore enclose a copy of these references for the file.

It is respectfully requested that each of the patents and publications listed be considered by the Examiner and made of record in this application.

Respectfully submitted,

/Lucy Padget/

Name: Lucy Padget
Dated: May 10, 2006
Reg. No.: L0074
Phone No.: 781-839-4182
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

<p align="center">INFORMATION DISCLOSURE STATEMENT Form PTO-1449</p>	Application Details	
	First Named Inventor	David William Tonge
	Filing Date	Herewith
	Application Serial No.	Not yet assigned
	Examiner Name	Not yet assigned
	Group Art Unit	Not yet assigned
	Attorney Docket No.	100815-1P US

U.S. PATENT DOCUMENTS							
Examiner Initials	Desig. ID	Document Number	Publication Date	Name	Class	Sub Class	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS									
Examiner Initials	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub Class	Filing Date	Abstract Only	English Language
	AA	WO 96 /40681	December 19, 1996	WO					Yes
	AB	WO 01 /44239	June 21, 2001	WO					Yes
	AC	WO 02 /49630	June 27, 2002	WO					Yes
	AD	WO 01 /60370	August 23, 2001	WO					No

OTHER DOCUMENTS		
(include Author, Title, Date and Place of Publication)		
Examiner Initials	Desig. ID	Document
	AE	CARDUCCI M A ET AL : "ENDOTHELIN RECEPTOR ANTAGONIST, ABT-627, FOR PROSTATE CANCER : INITIAL TRIAL RESULTS" JOURNAL OF UROLOGY, BALTIMORE, MD, US, Vol . 161, no . 4, SUPPL, April 1999 (1999-04), page 176,
	AF	NELSON J B ET AL : "THE ROLE OF ENDOTHELIN-1 AND ENDOTHELIN RECEPTOR ANTAGONISTS IN PROSTATE CANCER" BJU INTERNATIONAL, BLACKWELL SCIENCE, OXFORD, GB, vol . 85, no . SUPPL 2, April 2000 (2000-04), pages 45-48,
	AG	JARVIS M F ET AL : "ABT-627, AN ENDOTHELIN ETA RECEPTOR-SELECTIVE ANTAGONIST, ATTENUATES TACTILE ALLODYNIA IN A DIABETIC RAT MODEL OF NEUROPATHIC PAIN" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol . 388, no . 1, 24 January 2000 (2000-01-24), pages 29-35,
	AH	DATABASE WPI Section Ch, Week 200163 Derwent Publications Ltd ., London, GB; Class B03, AN 2001-565331

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.